Standish Fleming Net Worth

The estimated Net Worth of Standish Fleming is at least 659 千$ dollars as of 15 February 2006. Standish Fleming owns over 125,000 units of Acorda Therapeutics Inc stock worth over 659,267$ and over the last 19 years Standish sold ACOR stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Standish Fleming ACOR stock SEC Form 4 insiders trading

Standish has made over 1 trades of the Acorda Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Standish bought 125,000 units of ACOR stock worth 750,000$ on 15 February 2006.

The largest trade Standish's ever made was buying 125,000 units of Acorda Therapeutics Inc stock on 15 February 2006 worth over 750,000$. On average, Standish trades about 125,000 units every 0 days since 2006. As of 15 February 2006 Standish still owns at least 998,889 units of Acorda Therapeutics Inc stock.

You can see the complete history of Standish Fleming stock trades at the bottom of the page.

What's Standish Fleming's mailing address?

Standish's mailing address filed with the SEC is C/O ACORDA THERAPEUTICS, INC, 15 SKYLINE DRIVE, HAWTHORNE, NY, 10532.

Insiders trading at Acorda Therapeutics Inc

Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over 155,173,492$ worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth 17,085,546$ . The most active insiders traders include Capital Management Lp Scopi...、Ian F Smith、Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of 19,752$. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth 12,497$.

What does Acorda Therapeutics Inc do?

acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate

Complete history of Standish Fleming stock trades at Acorda Therapeutics Inc

Acorda Therapeutics Inc executives and stock owners

Acorda Therapeutics Inc executives and other stock owners filed with the SEC include:

• Ron Cohen,
  President,Chief Executive Officer, Director
• Dr. Ron Cohen M.D.,
  Founder, CEO, Pres & Director
• Burkhard Blank,
  Chief Medical Officer and Head of R&D
• Lauren Sabella,
  Chief Commercial Officer
• David Lawrence,
  Chief Business Operations, Principal Accounting Officer
• Dr. Burkhard Blank M.D.,
  Consultant
• Lauren M. Sabella,
  Chief Operating Officer
• Peder Jensen,
  Independent Director
• John Kelley,
  Non-Executive Independent Chairman of the Board
• Lorin Randall,
  Independent Director
• Sandra Panem,
  Independent Director
• Barry Greene,
  Independent Director
• Catherine Strader,
  Independent Director
• Neil S. Belloff Esq.,
  Gen. Counsel
• Michael A. Gesser M.B.A.,
  Chief Financial Officer
• Dr. Wise Young M.D., Ph.D.,
  Special Scientific Advisor
• Kerry M. Clem,
  Chief Commercial Officer
• Robert Morales,
  Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller
• Peter S. Carbone,
  Exec. VP of Quality
• Dr. Andrew R. Blight,
  Chief Scientific Officer Emeritus
• Denise J. Duca,
  Exec. VP of HR
• Tierney Saccavino,
  Exec. VP of Corp. Communications
• Andrew Mayer J.D.,
  Sr. VP, Deputy Gen. Counsel & Corp. Sec.
• Felicia Vonella,
  VP of Investor Relations
• Ian F Smith,
  Director
• Richard P. Batycky,
  Chief Tech. Off. & Site Head
• Steven M Rauscher,
  Director
• Capital Management Lp Scopi...,
  
• Kerry M Clem,
  Chief Commercial Officer
• Wise Young,
  Director
• Thomas Wessel,
  Chief Medical Officer
• Andrew A. Hindman,
  Chief Business Dev. Officer
• Barclay A Phillips,
  Director
• Capital Investments Ltd.Rid...,
  
• Mark R E Pinney,
  Director
• Michael Steinmetz,
  Director
• Standish Fleming,
  Director
• John H Friedman,
  Director
• Mary Fisher,
  Chief Operating Officer
• Michael W Rogers,
  Chief Financial Officer
• Enrique J. Carrazana,
  Chief Medical Officer
• Jane Wasman,
  President, Intl and GC
• Robert Morales,
  Interim PAO & PFO
• John Varian,
  Director
• Michael A Gesser,
  Chief Financial Officer
• Thomas M. Burns,
  Director
• Neil S. Belloff,
  General Counsel and Corp Secy